A medical graduate (M.D.) from the B. J. Medical College and Sassoon Hospitals, University of Pune, Maharashtra, Dr. Dhembare is a serial entrepreneur and has diversified in healthcare business in different verticals (clinical research, pharmaceuticals and medical diagnostics). He has extensive experience of more than 20 years in general management, corporate finance and strategic planning in healthcare industry.
His entrepreneurial journey started in 2007 when he set up Synapse Labs, a Contract Research Organization (CRO) that has been successfully inspected by global drug regulatory agencies which includes MHRA-UK, BfArM-Germany and ANSM-France.
He went ahead to set up Fidelity Diagnostics Private Limited in 2010, which is a chain of diagnostic centers providing high tech medical imaging and diagnostics services (CT, MRI, USG, Doppler etc.) to enable early detection and treatment of various diseases and disorders. In 2014, Fidelity Diagnostics has become India’s first chain of medical imaging centers accredited by NABH (National Accreditation of Hospitals and Healthcare Providers).
He also mentors a successful healthcare start up LIVEHEALTH as a board member which got “Best Healthcare Start-Up Award, 2016” in Apollo-THIT and e-Health national healthcare conferences, next round of funding from Nexus Venture Partners and have more than 1500 laboratories as clients in India, South East Asia, Middle East, Africa and South America including some of the big names in the industry like Reliance and Quest diagnostics in India, SDL in Saudi Arabia, BP healthcare in Malaysia, to name a few. Live health manages more than a million patient records on its platform every month.
Dr. Dhembare is also the promoter of Fidelity Life Sciences, a growing pharmaceutical manufacturer with world class manufacturing facilities and a complete portfolio of products in cardiology and diabetology. He has strong understanding of healthcare and pharmaceutical business and he has a vision to expand global presence of Fidelity group.
Before starting my entrepreneurial journey in 2007, he worked in pharmaceutical industry for 6-7 years in medical affairs and clinical research division where he was responsible for building clinical development programs for new chemical entities and both plain and complex generics for US and European markets.
He has various publications to his credit in national and international medical & scientific journals.
Dr. Geeta Dhembare is functioning as CEO of Fidelity Health Services (FHS) and is responsible for providing leadership to pharmacovigilance, medical information and medical writing team. She oversees a number of departments including operations, quality, human resources, facilities management and finance. She is responsible for development and implementation of organizational strategies and policies for growth.
Dr. Geeta is a medical graduate from C M Patel medical college, Mumbai and she has extensive experience in healthcare and medical informatics
She is also on the board of directors of Fidelity Diagnostics, a leading NABH accredited chain of medical imaging centres.
Dr. Koushik is a medical graduate with 20 years of experience including 12 years of experience in Pharmacovigilance. He has worked on various aspects of PV including but not limited to medical review, literature (end to end), aggregate reporting, RMPs, PSMF and also as subject matter expert for various PV activities.
He has previously worked with CROs (Quintiles), BPOs (Cognizant, Accenture, Interglobal solutions) and generic pharmaceutical companies (Lupin, Biocon) at different levels performing multiple PV activities, as subject matter expert, streamlining PV processes, project management, vendor management, people management and as business representative.
At FHS, he is responsible to provide drug safety leadership and ensure through understanding of adverse event management, workflow elements and compliance with local regulatory guidelines and Global Product Safety (GPS) policies, procedures and processes. He leads the pharmacovigilance team to fulfill operational targets with respect to number of cases processed, regulatory submissions and aggregate reports